JA
Therapeutic Areas
Jasper Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Briquilimab (JSP191) | Conditioning for allogeneic hematopoietic cell transplant in Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) | Phase 1/2 |
Leadership Team at Jasper Therapeutics
RM
Ronald Martell
Executive Chairman of the Board
WD
William D. (Bill) Lis
Chief Executive Officer and Board Member
JM
Jeet Mahal
Chief Business Officer
W(
Wen-Kai (Kevin) Weng
Chief Medical Officer
AS
Anna S. Truppel-Hartmann
Senior Vice President, Clinical Development
SG
Sheila Gujrathi
Board Member
CL
Connie L. Matsui
Board Member
EG
Edgar G. Engleman
Board Member
K(
Katherine (Kathy) High
Scientific Advisory Board Member
MP
Mortimer Poncz
Scientific Advisory Board Member